Francisco Barrera

Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Paul Angulo, Elisabetta Bugianesi, Einar S. Björnsson et al. · Gastroenterology · 2013 · 507 citations · Full text

Medicine, Internal Medicine, Hepatology +9

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Vlad Ratziu, Ladrón de Guevara, Rifaat Safadi et al. · Nature Medicine · 2021 · 215 citations · Full text

Medicine, Internal Medicine, Pharmacology +10

Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C

Konstantin Kazankov, Francisco Barrera, Holger Jon Mφller et al. · Hepatology · 2014 · 174 citations · Full text

Medicine, Infectious Diseases, Pathology +17

Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

Juan Pablo Arab, Melisa Dirchwolf, Mário Reis Álvares‐da‐Silva et al. · Annals of Hepatology · 2020 · 139 citations · Full text

Medicine, Endocrinology, Internal Medicine +14

The macrophage activation marker <scp>sCD</scp>163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease

Konstantin Kazankov, Francisco Barrera, Holger Jon Møller et al. · Liver International · 2016 · 112 citations · Full text

Medicine, Immunology, Pathology +17